HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH SEARCH RESULT		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kalantar-Zadeh, K. Articles by Lee, G. H. Search for Related Content PubMed PubMed Citation Articles by Kalantar-Zadeh, K. Articles by Lee, G. H.

The Fascinating but Deceptive Ferritin: To Measure It or Not to Measure It in Chronic Kidney Disease?

Kamyar Kalantar-Zadeh^*, Kourosh Kalantar-Zadeh, and Grace H. Lee

^* Division of Nephrology and Hypertension; Department of Pharmacy, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California; and Microelectronics and Materials Technology Center, School of Electrical and Computer Engineering, Royal Melbourne Institute of Technology, Melbourne, Victoria, Australia

Address correspondence to: Dr. Kamyar Kalantar-Zadeh, Division of Nephrology and Hypertension, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 West Carson Street, Torrance, CA 90502. Phone: 310-222-3891; Fax: 310-782-1837; E-mail: kamkal{at}ucla.edu

Although the emergence of erythropoiesis-stimulating agents has revolutionized the anemia management of chronic kidney disease (CKD) in the past two decades, strategies to assess iron (Fe) status and to provide Fe supplementation have remained indistinct. The reported cases of hemochromatosis in dialysis patients from the pre–erythropoiesis-stimulating agent era along with the possible associations of Fe with infection and oxidative stress have fueled the "iron apprehension." To date, no reliable marker of Fe stores in CKD has been agreed on. Serum ferritin continues to be the focus of attention. Almost half of all maintenance hemodialysis patients have a serum ferritin >500 ng/ml. In this ferritin range, Fe supplementation currently is not encouraged, although most reported hemochromatosis cases had a serum ferritin >2000 ng/ml. The moderate-range hyperferritinemia (500 to 2000 ng/ml) seems to be due mostly to non–Fe-related conditions, including inflammation, malnutrition, liver disease, infection, and malignancy. Recent epidemiologic studies have shown that a low, rather than a high, serum Fe is associated with a poor survival in maintenance hemodialysis patients. In multivariate adjusted models that mitigate the confounding effect of malnutrition-inflammation, serum ferritin <1200 ng/ml and Fe saturation ratio in 30 to 50% range are associated with the greatest survival in maintenance hemodialysis patients. Although ferritin is a fascinating molecule, moderate hyperferritinemia is a misleading marker of Fe stores in patients with CKD. It may be time to revisit the utility of serum ferritin in CKD and ask ourselves whether its measurement has helped us or has caused more confusion and controversy.

This article has been cited by other articles:

				S. Stancu, L. Barsan, A. Stanciu, and G. Mircescu Can the Response to Iron Therapy Be Predicted in Anemic Nondialysis Patients with Chronic Kidney Disease? Clin. J. Am. Soc. Nephrol., March 1, 2010; 5(3): 409 - 416. [Abstract] [Full Text] [PDF]

				A. Besarab, W. H. Horl, and D. Silverberg Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome Oncologist, September 1, 2009; 14(suppl_1): 22 - 33. [Abstract] [Full Text] [PDF]

				J. Zaritsky, B. Young, H.-J. Wang, M. Westerman, G. Olbina, E. Nemeth, T. Ganz, S. Rivera, A. R. Nissenson, and I. B. Salusky Hepcidin--A Potential Novel Biomarker for Iron Status in Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., June 1, 2009; 4(6): 1051 - 1056. [Abstract] [Full Text] [PDF]

				L. G. Coffman, D. Parsonage, R. D'Agostino Jr., F. M. Torti, and S. V. Torti Regulatory effects of ferritin on angiogenesis PNAS, January 13, 2009; 106(2): 570 - 575. [Abstract] [Full Text] [PDF]

				C. P. Kovesdy, G. H. Lee, and K. Kalantar-Zadeh Serum Ferritin: Deceptively Simple or Simply Deceptive? Lessons Learned From Iron Therapy in Patients With Chronic Kidney Disease Journal of Pharmacy Practice, December 1, 2008; 21(6): 411 - 419. [Abstract] [PDF]

				M. Rambod, C. P. Kovesdy, and K. Kalantar-Zadeh Combined High Serum Ferritin and Low Iron Saturation in Hemodialysis Patients: The Role of Inflammation Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1691 - 1701. [Abstract] [Full Text] [PDF]

				S. Tomasello Anemia of Chronic Kidney Disease Journal of Pharmacy Practice, June 1, 2008; 21(3): 181 - 195. [Abstract] [PDF]

				S. Amaral, W. Hwang, B. Fivush, A. Neu, D. Frankenfield, and S. Furth Serum Albumin Level and Risk for Mortality and Hospitalization in Adolescents on Hemodialysis Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 759 - 767. [Abstract] [Full Text] [PDF]